Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (Q38989105)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

phase III clinical trial

0 references

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Philip G Conaghan

9

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Désirée van der Heijde

7

object named as

Désirée van der Heijde

0 references

Robert Landewé

8

object named as

Robert Landewé

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Svetlana Yakupova

0 references

Jacek Szepietowski

1 reference

ORCID Public Data File 2021

Arthur Kavanaugh

4

object named as

Arthur Kavanaugh

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Iain B McInnes

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Philip J Mease

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Bruce Kirkham

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Christopher T Ritchlin

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Proton Rahman

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Alice B Gottlieb

10

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Hanno Richards

11

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Luminita Pricop

12

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Gregory Ligozio

13

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Manmath Patekar

14

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Shephard Mpofu

15

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

FUTURE 2 Study Group

16

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

0 references

publication date

26 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

386

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

9999

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1137-1146

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The dual nature of TH17 cells: shifting the focus to function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-17 receptor and its functional significance in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Editorial: emerging evidence for critical involvement of the interleukin-17 pathway in both psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Secukinumab in plaque psoriasis--results of two phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-17 signaling in host defense against Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961134-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)61134-5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38989105&oldid=1935718852"